News
Investors wiped $70 billion off Novo Nordisk’s market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...
Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...
Eli Lilly will soon bring a pill version to the market, with a version expected to debut at a lower price than injectable ...
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.
Facing a $70 billion market loss, Novo Nordisk appointed Maziar Mike Doustdar as its new CEO to navigate intensifying ...
It’s no secret that Ozempic isn’t going anywhere, but the weight loss drug category does seem to be rapidly evolving. According to J.P. Morgan Research, up to 30 million people could be on a ...
Partially as a result, Novo Nordisk stock has steadily declined since last summer. Over the past year, NVO shares are down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback